Autologous liver transplantation in end-stage hepatic alveolar echinoccossis with 51 patients’ experience–where do we stand?

Aji, Tuerganaili; Dong, Jun; Shao, Yingmei; Zhao, Jinming; Li, T.; Shalayiadang, Paizula; Ran, Boli; Jiang, Tao; Tuxun, Tuerhongjiang; Zhang, R.-Q.; He, Ying; Wen, H.; Huang, Jianfeng

doi:10.1016/s0168-8278(17)30484-1

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…10). Midterm results of such operations seem acceptable in comparison to conventional major hepatectomy with complex bile duct and vessel reconstruction or to liver transplantation (203,204). With an average follow-up of 22.5 months (range, 14 to 89 months) in 69 patients, overall mortality was 12%, complications higher than IIIa (according to the Clavien classification) were observed in 10 patients, and there was no recurrence (204).…”

Section: Treatment Of Aementioning

confidence: 98%

Echinococcosis: Advances in the 21st Century

Wen¹,

Vuitton²,

et al. 2019

View full text Add to dashboard Cite

SUMMARY Echinococcosis is a zoonosis caused by cestodes of the genus Echinococcus (family Taeniidae). This serious and near-cosmopolitan disease continues to be a significant public health issue, with western China being the area of highest endemicity for both the cystic (CE) and alveolar (AE) forms of echinococcosis. Considerable advances have been made in the 21st century on the genetics, genomics, and molecular epidemiology of the causative parasites, on diagnostic tools, and on treatment techniques and control strategies, including the development and deployment of vaccines. In terms of surgery, new procedures have superseded traditional techniques, and total cystectomy in CE, ex vivo resection with autotransplantation in AE, and percutaneous and perendoscopic procedures in both diseases have improved treatment efficacy and the quality of life of patients. In this review, we summarize recent progress on the biology, epidemiology, diagnosis, management, control, and prevention of CE and AE. Currently there is no alternative drug to albendazole to treat echinococcosis, and new compounds are required urgently. Recently acquired genomic and proteomic information can provide a platform for improving diagnosis and for finding new drug and vaccine targets, with direct impact in the future on the control of echinococcosis, which continues to be a global challenge.

show abstract

Section: Treatment Of Aementioning

confidence: 98%